Modulation of CD11c+ lung dendritic cells in respect to TGF‐β in experimental pulmonary fibrosis

Abstract Idiopathic pulmonary fibrosis (IPF) is a deadly, progressive lung disease with very few treatment options till now. Bleomycin‐induced pulmonary fibrosis (BIPF) is a commonly used mice model in IPF research. TGF‐β1 has been shown to play a key role in pulmonary fibrosis (PF). Dendritic cell (DC) acts as a bridge between innate and adaptive immune systems. The coexistence of chronic inflammation sustained by mature DCs with fibrosis suggests that inflammatory phenomenon has key importance in the pathogenesis of pulmonary fibrosis. Here, we investigated the modulation of DCs phenotypic maturation, accumulation in lung tissue, and expression of other lung DC subsets in respect to TGF‐β in PF. First, we established BIPF model in mice and blocked TGF‐β expression by the use of inhibitor SB431542. Accumulation of lung CD11c+ DCs is significantly higher in both inflammatory and fibrotic phases of the disease but that percentages got reduced in the absence of TGF‐β. TGF‐β initiates up‐regulation of costimulatory molecules CD86 and CD80 in the inflammatory phases of the disease but not so at fibrotic stage. Expression of lung DC subset CD11c+CD103+ is significantly increased in inflammatory phase and also in fibrotic phase of BIPF. Blocking of TGF‐β causes decreased expression of CD11c+CD103+ DCs. Another important lung DC subset CD11c+CD11b+ expression is suppressed by the absence of TGF‐β after bleomycin administration. CD11c+CD103+ DCs might have anti‐inflammatory as well as anti‐fibrotic nature in PF. All these data demonstrate differential modulation of CD11c+ lung DCs by TGF‐β in experimental PF.